Pharma Focus Europe

VIVEX Biologics, Inc. Unveils the Revolutionary CYGNUS® Dual Amniotic Allograft

Sunday, June 18, 2023

VIVEX Biologics, Inc., a prominent regenerative medicine company focused on developing naturally sourced treatments, has recently received positive news. The Centers for Medicare and Medicaid Services (CMS) has assigned a Q-code for their product called CYGNUS® Dual amniotic allograft. Effective from July 1, 2023, healthcare providers will be able to utilize the Q4282 code under the Healthcare Common Procedure Coding System (HCPCS) for CYGNUS Dual.

CYGNUS Dual is an amniotic allograft that undergoes a specialized processing technique known as Integrity Processing™, developed by VIVEX. This process retains the inherent properties of amniotic tissue, including a rich supply of extracellular matrix, growth factors, and cytokines. The product serves as a soft tissue barrier or wound covering, providing protection for damaged tissues while retaining over 600 signaling proteins. Notably, CYGNUS Dual is available in various sizes and features a dual-layered structure that allows for omnidirectional application with two outward-facing epithelial sides.

The addition of the HCPCS Q-code for CYGNUS Dual simplifies the reimbursement process for healthcare providers and enhances accessibility to this innovative product. This development is particularly significant for patients with chronic wounds, diabetic foot ulcers, and other challenging-to-heal wounds.

Rey Pascual, Co-President at VIVEX, expressed enthusiasm about the inclusion of CYGNUS Dual in CMS billing codes. Pascual emphasized that this achievement aligns with VIVEX's mission to improve patient care by developing tissue and biologics-based therapies that harness the body's healing and regenerative potential.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva